pipette
ESEspañol

Divergent medulloblastoma chromatin states disclose KDM2B as a selective dependency

Ran Tao, Serap Erkek, Beisi Xu, Yurika Matsui, Priya Mittal, Kyle S. Smith, Yiran Li, David Filipovic, Ruijie Xu, Qingsong Gao, Emily Darrow, Rahul Kumar, Mohamed Nadhir Djekidel, Richa Bajpai, Jennifer L. Hadley, Melissa Batts, Sara A. Lewis, Taha Soliman, Colleen A. Reilly, Natarajan V. Bhanu, Leena Paul, Hong Lin, Brian Gudenas, Kim Lowe, Marc Zapatka, Laura Sieber, David Jones, Marcel Kool, Sebastian M. Waszak, Volker Hovestadt, Ivo Buchhalter, Marina Ryzhova, Andrey Korshunov, Peter Lichter, Lukas Chávez, Lena M. Kutscher, Benjamin Aaron Garcia, Shondra M. Pruett‐Miller, Xin Zhou, Brent A. Orr, Giles W Robinson, Gang Wu, Jan O. Korbel, Jamy C. Peng, Stefan M. Pfister, Paul A. Northcott

Peer-reviewed journal

In the authors' words

Medulloblastoma is a biologically heterogeneous childhood cerebellar tumor harboring frequent chromatin-modifying gene alterations. How these alterations promote transcriptional programs governing malignancy remains poorly defined. To address this knowledge gap, we evaluated chromatin states across medulloblastoma subgroups by multi-modal integration of histone modifications with mutational, DNA methylation and transcriptomic profiles. A bivalent/poised enhancer (EnhBiv) state was specifically enriched at the promoters of neurodevelopmental genes in Group 3/4 medulloblastoma. Integrative bioinformatics coupled with chromatin occupancy studies identified aberrant KDM2B binding at EnhBiv-enriched promoters. CRISPR-mediated knockout or acute protein degradation of KDM2B selectively suppressed the growth of medulloblastoma models in vitro and in vivo. Mechanistically, KDM2B promotes sequential recruitment of Polycomb repressive complexes (PRC1/PRC2) and EnhBiv chromatin, thereby repressing neuronal differentiation programs. Collectively, we provide foundational insights into an epigenetic basis of medulloblastoma, nominating KDM2B as a selective dependency in high-risk subgroups that warrants consideration as a candidate therapeutic target.

Main resultThe abstract does not state a limitation.

Appeared: Saturday, September 26. Nature Genetics. Peer-reviewed journal.

DOI: 10.1038/s41588-026-02745-1